Search Results for keywords:"Drug Enforcement Administration"

VHG Labs, doing business as LGC Standards, has applied to the Drug Enforcement Administration (DEA) to register as an importer of specific controlled substances for analytical testing purposes. The DEA has announced this in the Federal Register and is accepting comments or objections from registered bulk manufacturers and other interested parties until February 24, 2025. Requests for a hearing related to this application must also be sent to the DEA by this date. The authorization sought does not include the importation of finished dosage forms approved by the Food and Drug Administration for commercial sale.

LTS Therapy Systems, LLC is seeking to become a registered importer of certain controlled substances for research and development purposes. The Drug Enforcement Administration (DEA) is asking for public comments or objections to this application by April 7, 2025. Comments must be submitted electronically through the Federal eRulemaking Portal. The company is not permitted to import these substances for commercial sale, and any registration approval will align with legal requirements.

The Drug Enforcement Administration (DEA) has decided to revoke Joely Keen's DEA registration because she is no longer authorized to handle controlled substances in Texas. Her licenses to practice as an advanced practice registered nurse (APRN) and registered nurse in Texas have been revoked, and she lacks a necessary prescriptive authority agreement with a supervising physician. Without these, she cannot legally prescribe or dispense controlled substances, resulting in the loss of her DEA registration. The order becomes effective on April 28, 2025.

VHG Labs, operating as LGC Standards, has submitted an application to the Drug Enforcement Administration (DEA) to become an importer of specific controlled substances, including synthetic cannabidiol and synthetic tetrahydrocannabinol. The company intends to supply these substances to research facilities for drug testing and analysis. Interested parties, such as existing manufacturers or applicants of these substances, can submit comments or request a hearing regarding this application before March 22, 2021. This notice does not permit the import of finished drugs for commercial sale.

The Drug Enforcement Administration (DEA) has announced that Sterling Wisconsin, LLC applied to register as a bulk manufacturer of certain controlled substances, specifically synthetic versions of Marihuana Extract, Marihuana, and Tetrahydrocannabinols. Interested parties can submit comments or objections electronically or request a hearing until May 27, 2025. The application was filed on January 30, 2025, and comments should be submitted via the Federal eRulemaking Portal as instructed.

Organic Consultants LLC, doing business as Cascade Chemistry, has applied to the Drug Enforcement Administration (DEA) to become a bulk manufacturer of certain controlled substances. Interested parties have until April 1, 2025, to submit comments or objections regarding the application or to request a hearing. Comments can be submitted electronically through the Federal eRulemaking Portal. The company intends to produce small amounts of these substances for internal use or to sell as analytical reference standard materials, with no other activities authorized for these drug codes.

Patheon API Manufacturing, Inc. has applied to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of certain controlled substances. The company intends to produce these substances as Active Pharmaceutical Ingredients (APIs) for its customers, specifically focusing on synthetic tetrahydrocannabinols. The public, including existing manufacturers and applicants, may submit comments or request a hearing on this application by April 20, 2021.

The Drug Enforcement Administration (DEA) issued an order to revoke the registration of Dr. Ajumobi Agu in Nevada due to violations of the Controlled Substances Act (CSA). Dr. Agu continued prescribing controlled substances even after his state medical and controlled substances licenses were suspended. The DEA concluded that his actions are inconsistent with the public interest and deemed him untrustworthy to handle such substances. As such, Dr. Agu will be unable to apply to renew or modify his DEA registration, effective May 16, 2025.

The Stepan Company has applied to the Drug Enforcement Administration (DEA) to be registered as an importer of certain controlled substances, as per the notice from the Justice Department's DEA. The application is to import these substances to manufacture other controlled substances, but not for commercial sale in finished form. Interested parties, such as current manufacturers or applicants, can comment or request a hearing about this application until April 9, 2025. Comments and hearing requests should be submitted through specified DEA addresses or electronically via the Federal eRulemaking Portal.

The Drug Enforcement Administration (DEA), part of the Department of Justice, has issued a final order establishing the aggregate production quotas for controlled substances in schedules I and II, and the annual needs for chemicals like ephedrine and pseudoephedrine for 2025. The order responds to public comments, particularly concerns about potential drug shortages, emphasizing that DEA aims to balance preventing drug misuse with ensuring adequate supply for medical and scientific needs. The quotas are set to address legitimate needs while considering factors like past usage data and potential diversion risks. Public concerns about opioid shortages were discussed, with the DEA noting that various external factors could affect drug availability and reassured that they are working with other agencies to mitigate such issues.